QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:ONCS

OncoSec Medical - ONCS Stock Forecast, Price & News

$1.68
-0.02 (-1.18%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.66
$1.76
50-Day Range
$1.61
$3.85
52-Week Range
$1.50
$31.90
Volume
52,812 shs
Average Volume
224,244 shs
Market Capitalization
$4.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.00

OncoSec Medical MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
6,447.6% Upside
$110.00 Price Target
Short Interest
Healthy
2.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

ONCS stock logo

About OncoSec Medical (NASDAQ:ONCS) Stock

OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in Pennington, NJ.

Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Stock News Headlines

ONCS.OQ - | Stock Price & Latest News | Reuters
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
OncoSec Announces Pricing of $3.5 Million Public Offering
New "Vertical" Technology Solves Solar Power's Major Flaw
Even conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.
OncoSec provides updates on cancer programs in new filing
OncoSec Announces Reverse Stock Split
OncoSec Cuts Workforce, Prioritizes Pipeline
OncoSec Medical to Restructure, Cut Jobs
OncoSec Medical To Reduce Staff By About 45%
Robert Arch joins OncoSec Medical as CEO
OncoSec appoints new finance chief
OncoSec Hikes on Start of Clinical Trial
See More Headlines
Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Company Calendar

Last Earnings
12/15/2022
Today
2/06/2023
Next Earnings (Estimated)
3/21/2023
Fiscal Year End
7/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCS
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$110.00
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$110.00
Forecasted Upside/Downside
+6,447.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-34,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.42 per share

Miscellaneous

Free Float
2,932,000
Market Cap
$4.99 million
Optionable
Not Optionable
Beta
1.65

Key Executives

  • Robert H. Arch
    President, CEO & Non-Independent Director
  • George Chi
    Chief Financial Officer
  • David Canton
    Vice President-Research & Development
  • Sandra Aung
    Chief Clinical Development Officer & Senior VP
  • Bridget O'Keeffe
    Vice President-Clinical Development













ONCS Stock - Frequently Asked Questions

Should I buy or sell OncoSec Medical stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCS, but not buy additional shares or sell existing shares.
View ONCS analyst ratings
or view top-rated stocks.

What is OncoSec Medical's stock price forecast for 2023?

1 brokers have issued twelve-month price objectives for OncoSec Medical's shares. Their ONCS share price forecasts range from $110.00 to $110.00. On average, they expect the company's stock price to reach $110.00 in the next twelve months. This suggests a possible upside of 6,447.6% from the stock's current price.
View analysts price targets for ONCS
or view top-rated stocks among Wall Street analysts.

How have ONCS shares performed in 2023?

OncoSec Medical's stock was trading at $1.68 at the start of the year. Since then, ONCS stock has increased by 0.0% and is now trading at $1.68.
View the best growth stocks for 2023 here
.

When is OncoSec Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our ONCS earnings forecast
.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) released its quarterly earnings results on Thursday, December, 15th. The biotechnology company reported ($4.50) earnings per share for the quarter.

When did OncoSec Medical's stock split?

OncoSec Medical's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano, Robert J Delaversano and Yuhang Zhao.
View institutional ownership trends
.

How do I buy shares of OncoSec Medical?

Shares of ONCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $1.68.

How much money does OncoSec Medical make?

OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $4.99 million. The biotechnology company earns $-34,180,000.00 in net income (profit) each year or ($18.1310) on an earnings per share basis.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for the company is www.oncosec.com. The biotechnology company can be reached via phone at (855) 662-6732, via email at investors@oncosec.com, or via fax at 858-430-3832.

This page (NASDAQ:ONCS) was last updated on 2/6/2023 by MarketBeat.com Staff